Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tarsus Pharmaceuticals, Inc

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Participate at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Announces Pricing of $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tickers TARS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.